Fraunhofer Gesundheit’s Post

CURIOUS 2024: Workshop “Potentials of AI to Transform Precision Medicine” 📅 Wednesday, July 10, 17:00 – 18:30 in Dome 5 At this year’s Curious Future Insight Conference, Dieter Fellner and Horst Hahn will chair a workshop exploring how AI solutions in healthcare can be transferred from research into clinical application. This addresses one use case that powerfully demonstrates the potential of AI to improve diagnostics and that is of great importance to oncology and the pharmaceutical industry: tissue analytics and AI-enabled digital pathology informed by Peta-scale datasets. Together with expert panelists Fabien Gaire, Katrien Grünberg, Ralf Kuhlen, and Stefan Wrobel, they will discuss questions such as ‣ Where are we currently regarding usage of AI in diagnostics? ‣ Is there a one-size-fits-all solution? ‣ What obstacles must be overcome? ‣ Is AI just a hype or will it transform pathology and diagnostics? ‣ How can the value for oncologists be maximized? ‣ Are we about to reinvent cancer care? 👉 https://s.fhg.de/rQJc #CURIOUS2024 #AI #BigData #Diagnostics #Oncology #TissueAnalytics #DigitalPathology #PrecisionMedicine Fraunhofer MEVIS Fraunhofer IAIS

🔬 Thrilled to share insights from my role as Project Manager in pioneering cervical cancer diagnostics through non-invasive spectroscopic methods. Our team's dedication, at #GuidedTherapeutics, to enhancing early detection led to significant breakthroughs, with our methods proving to detect cervical cancer much earlier than traditional pathology standards. Over two years of follow-up studies, we not only validated our technology but also provided hope for earlier and less invasive diagnostics. This work involved meticulous clinical study management, data collection, monitoring, and extensive collaboration with regulatory bodies like the FDA to ensure compliance and efficacy. As we published our findings and navigated the PMA process, it became clear that such innovations could drastically change patient outcomes. I'm proud to have contributed to this vital field, and I'm eager to explore further advancements in medical technology. #CervicalCancerAwareness #MedicalDevices #ClinicalResearch #FDA #Innovation #HealthTech #ProjectManager #PMA #cancerdiagnosis #noninvasive #spectroscopic #clinicalstudymanagement #datamonitoring #datacollection #guidedtherapeutics

Watch our on-demand webinar today where our Vice President of Product Innovation, James Cole, PhD sheds light on GenomOncology’s precision oncology solutions, with a focus on the GO Pathology Workbench, an end-to-end tertiary analysis and process enhancement solution for molecular pathology labs offering NGS testing. Watch the webinar today to learn how GenomOncology’s solutions can: 👉 Interpret variants and cases using their curated knowledge base of therapy approvals and guidelines, clinical trials, prognostic and diagnostic associations, published evidence, and more 👉 Prioritize clinical trials at an institution or based on distance from the patient 👉 Customize reports with no limitations, including setting up different reports for different tests (e.g. solid tumor vs. heme), or setting up multiple reports for a given test (e.g. PDF and XML) 👉 Set desired levels of automation to workflows to eliminate manual review and reduce turnaround time 👉 Support direct integration with LIS and EHR systems via API or file-based transfer (both inbound and outbound) Watch now to learn more: https://ow.ly/V6aE50QXzzM #pathology #ngs

CURIOUS 2024: Workshop “Potentials of AI to Transform Precision Medicine” 📅 Wednesday, July 10, 17:00 – 18:30 in Dome 5 At this year’s Curious Future Insight Conference, Dieter Fellner and Horst Hahn will chair a workshop exploring how AI solutions in healthcare can be transferred from research into clinical application. This addresses one use case that powerfully demonstrates the potential of AI to improve diagnostics and that is of great importance to oncology and the pharmaceutical industry: tissue analytics and AI-enabled digital pathology informed by Peta-scale datasets.  Together with expert panelists Fabien Gaire, Katrien Grünberg, Ralf Kuhlen, and Stefan Wrobel, they will discuss questions such as   ‣ Where are we currently regarding usage of AI in diagnostics?  ‣ Is there a one-size-fits-all solution?  ‣ What obstacles must be overcome?  ‣ Is AI just a hype or will it transform pathology and diagnostics?   ‣ How can the value for oncologists be maximized?   ‣ Are we about to reinvent cancer care?   👉 https://s.fhg.de/rQJc #CURIOUS2024 #AI #BigData #Diagnostics #Oncology #TissueAnalytics #DigitalPathology #PrecisionMedicine Fraunhofer IGD

How AI will change how we explain and treat cancer Many thanks to AbbVie commissioning a keynote on how AI will dramatically impact how we’ll perform as care providers, as drug developers and as patients. Here I take you on a 20min rollercoaster to explain AI, what it can do today and where it’s heading to redefine medicine and healthcare. The video (and an invite to a seminar on the future of hematology) is here: https://lnkd.in/eabKszrB #AbbVie

💡Case Study: Multi-Modal Biomarker Discovery 💡 View Now: https://bit.ly/3UoFFHx Multi-Modal analysis has huge promise to revolutionize diagnosis and treatment of disease. With imaging data and analysis traditionally being siloed/separated from OMICs, this promise has proven difficult to fulfill. Explore how Sonrai's multi-modal approach helped develop an early-stage breast cancer diagnostic test. Please reach out if you are having multi-modal analysis challenges or would just like to learn more about what Sonrai can offer. #diagnostics #AI #precisionmedicine #multimodaldata #imaging #multiomics #Sonrai #SonraiAnalytics #SonraiDiscovery

[Did you know?] We are harnessing the power of Artificial Intelligence in oncology clinical trials! 💡   Within Imaging Lab, we're providing new answers in a number of strategic areas that shape the outcome of oncology clinical trials. By leveraging #AI, we're not only expanding the scope of trials to include patients with early-stage diseases but also uncovering predictive biomarkers for drug candidate response.   Our mission? To revolutionize the clinical development landscape by optimizing the clinical development plan for new molecules, ultimately enhancing the success rates of clinical trials. 🚀   Want to learn more about Imaging Lab? Click here: https://lnkd.in/et-ieh42 #AI #OncologyTrials #MedicalImaging #Innovation #ImagingLab #DrugDevelopment

Exploring the Future of the Liquid Biopsy Market 🧬 https://lnkd.in/dVS4DXr5 As someone deeply invested in the healthcare industry, I'm excited to share insights about the rapidly evolving liquid biopsy market. This innovative approach to cancer detection and management is changing the game for both patients and healthcare professionals. Liquid biopsies offer a non-invasive method to detect cancer through a simple blood draw. Unlike traditional tissue biopsies, which can be painful and risky, liquid biopsies provide a more accessible, faster, and safer alternative. This method can detect cancer at an early stage, monitor treatment progress, and even identify genetic mutations. Market Growth and Impact 🚀 The liquid biopsy market is projected to grow significantly in the next few years. Factors driving this growth include advances in technology, increased prevalence of cancer, and a greater emphasis on personalized medicine. The market is not just about innovation but also about improving patient outcomes and experiences. CareDx, Inc., Eurofins Scientific Finland Oy, Exact Sciences, Immucor, Inc., mdxhealth, Menarini Silicon Biosystems, Guardant Health, Thermo Fisher Scientific, Illumina, Genomic Health, Myriad Genetics, RainDance Technologies, QIAGEN, Exosome Diagnostics Biocept, Inc. LungLife AI, Natera, Bio-Rad Laboratories #HealthcareInnovation #LiquidBiopsy #CancerDetection #PersonalizedMedicine #HealthcareIndustry

💡Case Study: Multi-Modal Biomarker Discovery 💡 View Now: https://bit.ly/3UoFFHx As the only company that can integrate multi-omics with imaging data, we enable diagnostics companies to generate new insights for novel biomarker discovery. Explore how Sonrai's multi-modal approach helped develop an early-stage breast cancer diagnostic test. #diagnostics #AI #precisionmedicine #multimodaldata #imaging #multiomics #Sonrai #SonraiAnalytics #SonraiDiscovery

The better we get at selecting patients most likely to respond to treatment, the more meaningful impact we will make with our medicines.    Historically, patient selection has been a ‘yes or no’ question based on inclusion and exclusion criteria, which is dependent on the presence or absence of expression of a given biomarker.   With the dawn of #AI and the giant wave of new ADCs that are awaiting clinical validation, we’re now beginning to consider this question in terms of the probability of benefit of treatment instead, based on biomarker expression profiles which we capture with sophisticated computational pathology methods such as Quantitative Continuous Scoring (QCS).   I was delighted to visit Munich again recently and to continue to partner with our Computational Pathology team, who continue to progress the application of QCS, our digital pathology approach, across the AstraZeneca Oncology portfolio.   Together, we are finding ways to knock down barriers and simplify our approach, so that this transformational technology is applied to our pipeline in a way that accelerates our efforts to bring precision medicines to patients.   Hadassah Sade Günter Schmidt Matt Hellmann Read more about Computational Pathology here: https://lnkd.in/eDhMQRMg